Column

Clinical Pathways GPS

10/20/2021

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.

Richard G. Stefanacci, DO, MGH,...

10/20/2021

Journal of Clinical Pathways

Trending From ACCC

Measurable Residual Disease Testing Implementation Roadmap for Patients With ALL

10/20/2021

American Association of Community Cancer Centers

The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.

The Association of Community...

10/20/2021

Journal of Clinical Pathways

Pharma Insights

COVID-19 and Diabetes: Strategies to Catch Up

10/20/2021

Cynthia Miller , MD, MPH, FACP;

Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.

Cynthia Miller, MD, MPH, FACP,...

10/20/2021

Journal of Clinical Pathways

Rajiv Panikkar, MD, Geisinger Cancer Institute Chair

Sponsored

Elsevier Partner Spotlight

Increasing Physician Awareness of Clinical Trials Through Oncology Pathways

10/20/2021

Rajiv Panikkar , MD;

Rajiv Panikkar, MD, explains how embedding clinical trials into the oncology pathways at Geisinger’s Cancer Institute has increased awareness of their clinical research program.

Rajiv Panikkar, MD, explains how...

10/20/2021

Journal of Clinical Pathways

Clinical Pathways GPS

Patients’ Care Journey via the Internet

09/24/2021

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Richard G Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the shift from patients being a passive party in their health to becoming an active force in every aspect of care, from diagnosis to treatment to adherence.

Richard G Stefanacci, DO, MGH,...

09/24/2021

Journal of Clinical Pathways

Trending From ACCC

Defining the Role of Oncology Advanced Practitioners in Equitable Cancer Care Delivery

09/24/2021

Association of Community Cancer Centers

The Association of Community Cancer Centers defined 10 feasible and impactful opportunities for oncology APs to play a greater role in equitable cancer care delivery.

The Association of Community...

09/24/2021

Journal of Clinical Pathways

Pharma Insights

Impact of NextGen Access Decision Makers on Health Care Services and Therapies

09/23/2021

Elizabeth Oyekan , PharmD, FCSHP, CPHQ;

Dominic Galante , MD, MS, PhD, CPCC;

Elizabeth Oyekan, PharmD, and Dominic Galante, MD, discuss next generation access decision makers and value-based care in the midst of the pandemic and beyond.

Elizabeth Oyekan, PharmD, and...

09/23/2021

Journal of Clinical Pathways

Editor's Page

Catching Up After Summer Break

08/20/2021

Winston Wong , PharmD;

Winston Wong, PharmD, discusses the articles in this issue, which include research examining the impact of a SARS-CoV-2 infection on patients previously diagnosed with immune-mediated inflammatory diseases, and results from a study examining...

Winston Wong, PharmD, discusses...

08/20/2021

Journal of Clinical Pathways

COA Viewpoint

SCOTUS Upholds Limits on Pharmacy Benefits Managers

08/19/2021

Ricky Newton , CPA;

Ricky Newton, CPA, weighs in on states seeking to enact legislation regulating pharmacy benefit managers, which he describes as the "next frontier" in the ongoing war with the pharmacy benefit managers.

Ricky Newton, CPA, weighs in on...

08/19/2021

Journal of Clinical Pathways

Clinical Pathways GPS

Clinical Pathways Improving Management of Rare Conditions

08/19/2021

Richard G. Stefanacci , DO, MGH, MBA, AGSF, CMD;

Richard Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the unique opportunity clinical pathways have to improve the diagnosis of rare diseases, in addition to their role in treatment.

Richard Stefanacci, DO, MGH,...

08/19/2021

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Column

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products